TrialAmerican journal of clinical dermatology2023

Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.

Elaine C Siegfried et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.